Indomesa

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Indomesa

What is Indomesa? Defining the Drug Entity

Property Description
Active Ingredient Indometacin
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID)
Forms Capsules, Suppositories, Topical Gel/Cream
Common Use Reduction of pain, fever, and inflammation
Origin Synthetic (Indoleacetic acid derivative)

Indomesa is a medicinal preparation containing the potent active substance Indometacin (also known as Indomethacin), which is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This distinction places it within a core group of synthetic compounds used to manage general discomfort and inflammatory processes. As an indoleacetic acid derivative, Indometacin is clinically recognized for its high potency when systemic delivery is required.

The formulation is typically a prescription-only (Rx) medication, underscoring its authoritative use in situations where strong anti-inflammatory action is needed. The compound is designed to work powerfully against inflammation and pain.

Composition, Origin, and Available Forms

The active compound, Indometacin, is entirely synthetic in origin and is typically formulated as a single-ingredient product. The drug is provided in multiple high-level physical forms to accommodate different needs, primarily as capsules for systemic oral effects, suppositories for rectal delivery, and topical gels or creams for localized application.

These varying dosage forms facilitate flexible routes of administration—oral, rectal, and topical. In each instance, the Indometacin is combined with pharmaceutical excipients or an aqueous/alcoholic base to ensure proper stability and delivery, maintaining its core single-ingredient identity across different preparations.

Indomesa's General Therapeutic Purpose

The general therapeutic purpose of Indomesa is to powerfully relieve the three core symptoms of inflammatory reactions: pain, fever (antipyresis), and inflammation itself. Its effect stems from its ability to intervene in the internal mechanism that generates these symptoms.

This overarching benefit is supported by pharmacological studies confirming that Indometacin functions as a potent Cyclooxygenase (COX) inhibitor, thereby limiting the synthesis of prostaglandins—the specific compounds that propagate pain signals and inflammatory swelling. By controlling this specific biochemical pathway, the medicine establishes its generalized use for alleviating discomfort and elevated body temperature associated with inflammatory conditions.

Regulatory References

  1. National Library of Medicine, MedlinePlus
  2. StatPearls - NCBI Bookshelf

What side effects are possible with Indomesa?

Indomesa (Indomethacin) is a nonsteroidal anti-inflammatory drug (NSAID) with a profile of potential side effects and safety considerations common to this class of medication.

Common Side Effects

Side effects that are frequently reported include issues related to the gastrointestinal (GI) tract and central nervous system (CNS), such as:

  • Headache and dizziness
  • Nausea, vomiting, indigestion, heartburn, and abdominal pain

Serious Safety Warnings

Indomesa carries the risk of serious side effects, which require immediate medical attention if symptoms occur:

  • Cardiovascular Thrombotic Events: Indomesa can increase the risk of serious events, including heart attack and stroke. This risk may be higher with long-term use and in patients with pre-existing heart disease. It is generally contraindicated for pain management immediately before or after coronary artery bypass graft (CABG) surgery.
  • Gastrointestinal Risk: The medication can cause serious GI adverse events, such as bleeding, ulceration, or perforation of the stomach or intestines, which may be fatal. These events can occur without warning, particularly in older adults.

When to Seek Immediate Medical Help

Stop taking the medication and seek emergency care if you experience:

  • Signs of Heart Attack or Stroke: Chest pain, shortness of breath, sudden numbness/weakness, or slurred speech.
  • Signs of GI Bleeding: Black or tarry stools, or vomiting material that looks like coffee grounds.
  • Signs of Allergic Reaction: Hives, difficulty breathing, or swelling of the face, tongue, or throat.

Precautions and Contraindications

Indomesa should be used with caution, or avoided entirely, in patients with a history of:

Condition Safety Information
Active GI bleeding or ulcers Increased risk of perforation and bleeding.
Severe kidney or liver disease Requires monitoring or contraindication.
Uncontrolled hypertension/Heart failure Can cause new or worsening high blood pressure and fluid retention.
Aspirin-sensitive asthma Increased risk of severe allergic reactions (e.g., anaphylaxis).

It is essential to inform your healthcare provider about your complete medical history and all other medications, as Indomesa can interact with blood thinners, diuretics, and other NSAIDs, increasing the risk of adverse effects.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Indomesa (Indometacin) may present with documented systemic manifestations, including severe headache, nausea, and vomiting, which can sometimes involve blood. Central nervous system effects listed in regulatory information include dizziness, confusion, extreme tiredness, and unsteadiness. Sensory effects such as ringing in the ears (tinnitus) are also noted. Less frequently reported signs may include high or low blood pressure and increased heart rate.

These symptoms can escalate to severe, life-threatening outcomes, including generalized seizures and coma. Regulatory documents also highlight the risk of serious gastrointestinal bleeding and acute kidney damage, which may manifest as little or no urine output. The prognosis is determined by the amount swallowed and the speed with which treatment is received. The potential for permanent kidney damage requiring dialysis is a documented, severe outcome.

Because no specific antidote is known for Indometacin overdose, regulatory authorities mandate that any suspected overdose requires immediate action. Individuals are required to seek medical help right away and contact the local emergency number or poison control center at once. Management is symptomatic and supportive, involving monitoring of vital signs, blood tests, and procedures such as activated charcoal or gastric lavage to manage the documented manifestations and complications.

Therapeutic Uses of Indomesa

What Indomesa Treats: Main Uses and Benefits

Indomesa (Indometacin) is generally used in situations involving certain distressing symptoms, primarily addressing symptoms related to inflammatory or irritative states that create noticeable physiological strain. The medication may assist with managing symptom clusters that become intense or disruptive, helping patients maintain a sense of stability when symptoms are more noticeable. This therapeutic scope is relevant for several areas.

Indomesa is commonly used to help with conditions characterized by periods of heightened symptoms such as Rheumatoid Arthritis, Ankylosing Spondylitis, Osteoarthritis, acute Gouty Arthritis flares, and localized inflammation due to Bursitis and Tendinitis. It is applied in addressing symptom clusters that include joint pain, associated swelling, and stiffness. Symptomatic relief contributes to improved comfort during periods of heightened symptoms and may assist with maintaining functional stability.

It is also relevant for certain contexts, including specific headache disorders. Additionally, it is used in a clinical setting for preterm infants to facilitate the closure of the Patent Ductus Arteriosus (PDA), an intervention relevant in contexts involving heightened systemic burden.


Quick Fact: Relief for Inflammatory Pain

Quick Fact: Relief for Inflammatory Pain (e.g., Joint Pain, Swelling, and Stiffness) in conditions like Arthritis and Gout.

Regulatory References

  1. National Institutes of Health's DailyMed

Eligibility and Restrictions for Use

The eligibility to use Indomesa is strictly governed by patient characteristics and existing clinical conditions, as defined in official regulatory documents. Use is contraindicated (prohibited) in several specific patient groups:

  • Hypersensitivity: Individuals with a known hypersensitivity to the active substances or any excipients.
  • Liver Disease: Patients with active liver disease or unexplained, persistent elevations in liver enzymes (serum transaminases exceeding 3 imes the upper limit of normal).
  • Severe Renal Impairment: Patients with severe renal impairment (creatinine clearance <30 ml/min) for all doses.
  • Pregnancy and Lactation: Women who are pregnant, breast-feeding, or of childbearing potential and not using appropriate contraceptive measures.

Use is not recommended in children and adolescents under 18 years of age, as safety and efficacy have not yet been established in this population. It is also not recommended for patients with moderate or severe hepatic impairment (Child-Pugh score 7). Restrictions also apply to patients with moderate renal impairment (creatinine clearance <60 ml/min) and those of Asian ancestry, who require a lower starting dose. Patients with rare hereditary problems, such as galactose intolerance, are also excluded from use.

What should I know about interactions with other medicines?

The official interaction profile for Indomesa is defined by mandated regulatory warnings concerning pharmacokinetic changes and pharmacodynamic risk reinforcement. Co-administration is formally contraindicated in the setting of Coronary Artery Bypass Graft (CABG) surgery. Concomitant use with other nonsteroidal anti-inflammatory drugs (NSAIDs) or analgesic doses of Aspirin is generally not recommended due to increased gastrointestinal risk.

Documented Pharmacokinetic and Pharmacodynamic Interference

Indomesa affects the clearance of several medicines. It reduces the renal excretion of both Lithium and Digoxin, resulting in elevated serum concentrations of both co-administered substances. Chronic concurrent use of Aspirin may decrease Indomesa blood levels. The medicine may diminish the therapeutic efficacy of Antihypertensives (ACE Inhibitors, ARBs) and certain Diuretics by Pharmacodynamic interference. Co-administration with Potassium-Sparing Diuretics is associated with an increased risk of hyperkalemia. Furthermore, combining with Anticoagulants (e.g., Warfarin) or SSRIs/SNRIs increases the risk of bleeding.

Specific Restrictions and Contexts

Officially documented interactions include the risk of serious gastrointestinal bleeding when combined with Alcohol. A specific caution notes that the combined use of ACE Inhibitors or ARBs carries an increased risk of worsening renal function in elderly or renally impaired populations.

Mechanism of Action

The activity of Indometacin involves interaction with biological targets to alter the synthesis of specific lipid mediators. The drug's mechanism operates across central and peripheral systems, primarily through enzymatic blockade.

Nonselective Enzymatic Blockade

The core action of Indometacin is achieved by functioning as a nonselective inhibitor of the Cyclooxygenase (COX) enzymes, specifically targeting both the constitutive COX-1 and the inducible COX-2 isoforms. This mechanism prevents the conversion of arachidonic acid into prostaglandins (PGs) and thromboxanes, which are lipid mediators known to be involved in thermoregulation and processes that lead to localized swelling and heat.

Modulation of Central and Peripheral Signaling

This blockade of PG synthesis results in a dual action on key regulatory systems. Centrally, the drug suppresses PGE2 in the hypothalamus, which prevents the pathological elevation of the thermoregulatory set-point. Peripherally, the reduction in PGE2 reduces the sensitization of nociceptors (pain-sensing nerves) to other chemical irritants. This results in a decrease in central thermal activity and a reduction in the excitability of peripheral sensory neurons.

Dosage and Administration Information

Indomesa (Indometacin) is officially available for systemic use via the oral and rectal routes, and for a highly specific purpose, via the intravenous (IV) route. Oral forms, including immediate-release and extended-release capsules, are typically started at a low initial dose, such as 25 mg two or three times daily, for chronic conditions like arthritis. The overarching principle requires the use of the lowest effective dose for the shortest duration to achieve therapeutic goals.

The medicine's administration schedule varies by form and context. Immediate-release capsules are administered multiple times daily, and the dose may be adjusted at weekly intervals for maintenance therapy. For acute episodes, such as gouty arthritis, a higher dose of 50 mg three times daily is used, followed by rapid reduction to cessation once symptoms are controlled. The oral forms must always be taken with or immediately after food to help manage gastrointestinal tolerance. All capsules must be swallowed whole and are not to be opened or crushed.

In specialized settings, the IV formulation is reserved for neonates, where a three-dose course is given at 12 to 24 hour intervals, with the dose determined by the infant's postnatal age. This intravenous powder requires reconstitution with preservative-free diluents and subsequent administration as a slow infusion over 20 to 30 minutes.

Recent Clinical Evidence

Overview of Studies for Indomesa

Evidence for Managing Arthritis and Chronic Joint Inflammation

Research on Indomesa's study in chronic inflammatory joint conditions, including Rheumatoid Arthritis, Ankylosing Spondylitis, and Osteoarthritis, has included short-term Randomized Controlled Trials (RCTs). These studies primarily monitored patient-reported outcomes such as changes in joint pain, swelling, stiffness, and assessments of daily physical function. Findings describe patterns observed over short-term intervals (weeks to a few months).

For Osteoarthritis, the evidence quality is generally categorized as moderate. Long-term effects are not fully established, and much of the research documents short-term symptomatic changes rather than long-term condition evolution.

Research on Acute Flare Management

Evidence for Acute Gouty Arthritis flares has included short-term RCTs that examined how symptoms evolved in the observed populations, with outcomes focusing on rapid changes in pain and localized swelling over a few days. For localized inflammation, such as Bursitis and Tendinitis, evidence is based on clinical evaluations and regulatory summaries, with large-scale RCTs being limited.

Research in Preterm Infants: Patent Ductus Arteriosus (PDA) Closure

Dedicated high-level RCTs and systematic reviews studied Indomesa for PDA closure in preterm infants, monitoring short-term closure rates and long-term neonatal outcomes. Short-term RCTs reported a measurable pattern in the rate of ductal closure. However, findings regarding the long-term impact on major morbidities were often mixed and inconsistent across systematic reviews. The certainty remains low regarding the compound's definitive influence on the long-term health trajectory of these infants.

What is Still Uncertain About Indomesa Research

A significant gap is the limited information for long-term outcomes across all chronic indications, especially when assessing the durability of functional changes. Furthermore, evidence quality varies across studies, and comparative evidence is lacking in some contexts, meaning direct comparisons against all newer anti-inflammatory therapies are not universally available. Research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Indomesa (FAQ)


Q: Can Indomesa be taken on an empty stomach?

A: According to official product instructions, oral forms of Indomesa should always be taken with or immediately after food. This requirement is noted in regulatory information to help manage the risk of gastrointestinal side effects, such as stomach upset or irritation.


Q: What are the official storage requirements for Indomesa?

A: Regulatory documents require Indomesa capsules to be kept at a Controlled Room Temperature, which is 20 to 25 C (68 to 77 F). The medicine must be protected from excessive moisture, heat, and direct light, and official guidance specifies that it must be stored in its original container, out of the sight and reach of children.


Q: Can Indomesa be split, crushed, or chewed?

A: Official instructions state that Indomesa capsules must be swallowed whole and should not be opened, crushed, or chewed. Regulatory guidance states this is done because altering the capsule's form may change the way the medicine works.


Q: Is Indomesa a newer drug or has it been around for a while?

A: Indomesa (Indometacin) is not considered a newer drug. Official regulatory history indicates that it was first approved by the U.S. Food and Drug Administration (FDA) in 1965, meaning it has been used in a clinical setting for several decades.


Q: Is Indomesa a Schedule I, II, III, IV, or V substance?

A: Indomesa is not classified as a controlled substance under the U.S. DEA (Drug Enforcement Administration) schedules. It is regulated as a prescription-only (Rx) medication due to its potency and potential side effects, but it does not fall into the controlled substance categories.


Q: What does 'contraindicated' mean in the context of Indomesa?

A: In regulatory documents, 'contraindicated' means that the use of Indomesa is formally prohibited because the risks clearly outweigh any potential benefits in a specific patient situation. Examples include having a known allergy to the medicine or using it immediately before or after coronary artery bypass graft (CABG) surgery.


Q: How is Indomesa eliminated from the body?

A: After working in the body, Indomesa is eliminated through a combination of natural processes. These include metabolism (being broken down chemically), followed by excretion in the urine (renal excretion) and excretion in the feces (biliary excretion).


Q: Is Indomesa the same type of medicine as [similar common drug name]?

A: Indomesa contains the active ingredient Indometacin, which is officially categorized as a Nonsteroidal Anti-inflammatory Drug (NSAID). This is a common class of medicine used to address pain, fever, and inflammation, placing it in the same general family as some other common medicines.


Q: How quickly does Indomesa start to work after taking it?

A: The onset of effect is described in regulatory documents as varying by the condition being treated. For acute conditions like gouty arthritis, studies have reported that definite relief of pain often begins within two to four hours following the start of treatment.


Q: What is the time frame for seeing the full effects of Indomesa?

A: The time frame for full symptomatic relief is described as varying based on the specific condition. For acute gouty arthritis, for example, official regulatory information indicates that tenderness and heat usually subside within 24 to 36 hours, and swelling generally disappears within 3 to 5 days.


Q: Does Indomesa cause weight gain or weight loss?

A: Regulatory documents list weight gain and fluid retention (edema) as possible side effects. Patients are instructed by their prescribers to report signs of unexplained weight gain to a healthcare professional.


Q: How long can a person stay on Indomesa treatment?

A: Official guidance emphasizes using the lowest effective dosage for the shortest duration necessary to achieve treatment goals. The decision to use the drug long-term is made under professional supervision, in adherence to this principle.


Q: Does taking Indomesa affect sleep patterns?

A: Possible effects on the Central Nervous System (CNS) are listed in regulatory documents. These effects include dizziness and drowsiness, which may be associated with changes to alertness.


Q: Is Indomesa considered a blood thinner?

A: Indomesa is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID), not a blood thinner (anticoagulant). However, regulatory warnings clearly state that it may increase the risk of bleeding, particularly when used in combination with anticoagulant medicines.


Q: Does Indomesa show up on standard drug tests?

A: Since Indomesa is not classified as a controlled substance under U.S. law, it is generally not included in standard, broad drug screening panels.


Q: What is the typical age range of people using Indomesa?

A: Indomesa is typically prescribed for adults who have specific inflammatory conditions. Specialized intravenous forms are reserved for a distinct, limited purpose in neonates (newborns) under highly specific medical contexts.


Q: Are there dietary restrictions specifically listed for Indomesa?

A: Official documents specify that the medicine should be taken with food, as required by the dosage instructions. Furthermore, regulatory warnings advise against the combined use of alcohol due to the significantly increased risk of serious gastrointestinal bleeding. No other specific food-based restrictions are commonly listed.


Q: Is Indomesa known to cause dry mouth?

A: Dry mouth is listed in regulatory documentation as a possible side effect, though it is reported to occur only uncommonly during treatment with Indomesa.


Q: What are the possible risks of taking Indomesa for more than five years?

A: Regulatory warnings emphasize that the risk of serious side effects, such as cardiovascular thrombotic events (heart attack and stroke) and gastrointestinal events (bleeding/ulcers), may increase with the duration of use. Long-term use is carried out under professional supervision.


Q: Does Indomesa have any known impact on fertility?

A: Regulatory documents note that the use of drugs in the NSAID class, including Indomesa, has been associated with a condition known as reversible infertility. Withdrawal of the medicine is a consideration noted for women who have difficulty conceiving.


Q: Can I take other medications at the same time as Indomesa?

A: Regulatory documents contain a dedicated section on Drug Interactions that lists medicines and products which should be avoided or used with caution alongside Indomesa. This requirement underscores the importance of having all drug interactions reviewed by a professional before use.


Q: Does Indomesa require refrigeration?

A: Indomesa capsules and oral suspension are officially required to be stored at Controlled Room Temperature (20 to 25 C) and should not be refrigerated or frozen, as extreme cold can destabilize the product.

How should Indomesa be stored and disposed of?

How to Store and Dispose of Indomesa (Indometacin)

Official regulatory documentation requires specific storage conditions to maintain product stability and ensure safety. All forms of Indometacin must be stored out of the sight and reach of children.

Indometacin capsules must be stored at Controlled Room Temperature, 20 to 25 C (68 to 77 F), protected from moisture, and kept in the original container. The oral suspension must be stored at room temperature, protected from heat, moisture, and direct light, and must not be frozen.

Official Disposal Guidelines

Expired or unused Indometacin should be disposed of by using a drug take-back program or mail-back option when available. If those options are not accessible, the product must be mixed with an undesirable substance (such as dirt or cat litter), sealed in a container, and placed in the household trash. Identifying information must be removed from the original label before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Indomesa found in:

A-Z Index: